Genematrix Pushes Back GMAI-02 Phase 1 Trial Expected Completion to August 2028

• Genematrix’s Oct. 27, 2026, correction moved the GMAI-02 Phase 1 trial’s expected completion to Aug. 28, 2028, from June 30, 2027.
• The revised date reflects the clinical trial contract’s end date.
• Seoul National University Hospital was confirmed as the trial site; C&R Research will serve as the contract research organization.
• The hepatitis A vaccine trial targets 30 healthy adult men in South Korea.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genematrix Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261027900143), on October 27, 2026, and is solely responsible for the information contained therein.